SEC Comment Letter for X4 Pharmaceuticals, Inc (XFOR) (CIK 0001501697) (XFOR) — Feb 8, 2019
X4 Pharmaceuticals, Inc (XFOR) (CIK 0001501697)
Date: Feb. 8, 2019 · CIK: 0001501697 · Accession: 0000000000-19-001674
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-228929
Letter
February 7, 2019 Michael Gray President and Chief Executive Officer, Chief Financial Officer Arsanis, Inc. 890 Winter Street, Suite 230 Waltham, MA 02451 Re:Arsanis, Inc. Registration Statement on Form S-4 Filed December 20, 2018 File No. 333-228929 Dear Mr. Gray : This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Todd Schiffman at 202-551-3491 with any questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance
Show Raw Text
February 7, 2019
Michael Gray
President and Chief Executive Officer, Chief Financial Officer
Arsanis, Inc.
890 Winter Street, Suite 230
Waltham, MA 02451
Re:Arsanis, Inc.
Registration Statement on Form S-4
Filed December 20, 2018
File No. 333-228929
Dear Mr. Gray :
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Todd Schiffman at 202-551-3491 with any questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance